Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C
- PMID: 8200260
- DOI: 10.1007/BF02093793
Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C
Abstract
Using conventional statistical analysis and multiple regression analysis, we investigated the viral and host factors that influence the response to recombinant interferon-alpha 2a therapy in patients with chronic hepatitis C. A total of 36 patients was randomly assigned to three administration schedules, 12 patients in each. Response to treatment was set as the criterion variable. Four variables were statistically significant in the conventional method in predicting a good therapeutic outcome: HCV genotype III and IV, lower histology activity index (HAI) score for liver, higher total dose of interferon administration, and lower serum HCV RNA concentration. In multiple regression analysis, a combination of the above four variables resulted in a higher multiple correlation coefficient (R = 0.84, P < 0.0001) using a stepwise method. Of those four, HCV genotype had the highest absolute value of standard partial regression coefficient (0.51). The HCV RNA concentration was correlated with HCV genotype and HAI score, whereas HCV genotype and HAI score showed no correlation. Thus, HCV RNA concentration was not statistically significant in multiple regression analysis. These findings indicate that HCV genotype, HAI score, and schedule of administration can be important predictors of the response to interferon therapy.
Similar articles
-
Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.J Med Virol. 1995 Jun;46(2):162-8. doi: 10.1002/jmv.1890460215. J Med Virol. 1995. PMID: 7636506
-
Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.Hepatology. 1997 Sep;26(3):747-54. doi: 10.1002/hep.510260330. Hepatology. 1997. PMID: 9303508 Clinical Trial.
-
Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C.Transl Res. 2006 Aug;148(2):79-86. doi: 10.1016/j.trsl.2006.03.004. Transl Res. 2006. PMID: 16890148
-
Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.Hepatology. 1997 Sep;26(3 Suppl 1):101S-107S. doi: 10.1002/hep.510260718. Hepatology. 1997. PMID: 9305673 Review.
-
Treatment of HCV liver disease by recombinant interferon alpha.Nephrol Dial Transplant. 1996;11 Suppl 4:56-7. doi: 10.1093/ndt/11.supp4.56. Nephrol Dial Transplant. 1996. PMID: 8918757 Review.
Cited by
-
Hepatitis C virus genotypes in Korea and their relationship to clinical outcome in type C chronic liver diseases.Korean J Intern Med. 1997 Jan;12(1):21-7. doi: 10.3904/kjim.1997.12.1.21. Korean J Intern Med. 1997. PMID: 9159033 Free PMC article. Clinical Trial.
-
Detection and typing of hepatitis C RNA in liver biopsies and its relation to histopathology.Virchows Arch. 1996 Dec;429(6):353-8. doi: 10.1007/BF00198439. Virchows Arch. 1996. PMID: 8982379
-
Genotypes and virus load in patients with hepatitis C infection.Infection. 1995 May-Jun;23(3):133-8. doi: 10.1007/BF01793852. Infection. 1995. PMID: 7499000
-
Past and present hepatitis G virus infections in areas where hepatitis C is highly endemic and those where it is not endemic.J Clin Microbiol. 1998 Jan;36(1):110-4. doi: 10.1128/JCM.36.1.110-114.1998. J Clin Microbiol. 1998. PMID: 9431931 Free PMC article.
-
In-Vitro Transcription analysis of NS5A from HCV-3a circulating in Pakistani patients with chronic hepatitis C and their differential response to antiviral therapy.Pak J Med Sci. 2017 Sep-Oct;33(5):1236-1241. doi: 10.12669/pjms.335.12973. Pak J Med Sci. 2017. PMID: 29142571 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical